KIAT EUREKA Network Advanced Bio International Joint R&D

KIAT EUREKA Network Advanced Bio International Joint R&D is KIAT's first EUREKA-channel joint research route dedicated to advanced bio, including medical devices and biotech. Announced on 27 April 2026 as MOTIE's 2026 EUREKA Network Advanced Bio International Joint R&D Project, it extends Korea's industrial technology cooperation into cross-border bio work with European partners. It is also the first time Korea has supported international joint research in the advanced bio sector through EUREKA, and KIAT tied the launch to the EUREKA Global Innovation Summit in Basel and the Korea-Switzerland Biohealth Partnership Forum. The instrument is a grant on an annual cycle, with Korean registration and operations required and a consortium structure built into the design. Eligibility allows for-profit applicants and also permits universities, non-profits, and research organisations as partners, while individuals are excluded. The technical band runs from TRL 4 to 8, and the programme asks for 25 percent matching support. This track is strongest for Korean bio and medtech teams that can line up a European industrial or research partner and use the summit and forum to validate the collaboration. KIAT's own framing focuses on technical consultation and partner discovery, so applicants that arrive with a defined research question and a credible cross-border division of labour fit best. Because the programme is new, the useful signal is not legacy history but whether the team can convert European matchmaking into a working consortium.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.